Urolog. pro Praxi, 2008; 9(2): 64-68

Drugs influencing coagulation in urology

MUDr. Kamil Belej Ph.D., FEBU
Urologické oddělení Ústřední vojenská nemocnice, Praha

Drugs affecting blood coagulation have been increasingly used to prevent and treat many vascular and haematologic diseases. Patients on these medication present management problems when attending for urological invasive procedures. There is no consensus of opinion on the appropriate management of these patients before and after surgery. In this article we review existing data on the management of these patients and we make some recommendations based on current knowledge. Until more information is available, those prescribing anticoagulants and those performing surgery must communicate with each other and team approach is crucial in order to achieve this.

Keywords: coagulation, surgery, warfarin, heparin, antiplatelet drugs

Published: May 21, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Belej K. Drugs influencing coagulation in urology. Urol. praxi. 2008;9(2):64-68.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 204S-233S. Go to original source... Go to PubMed...
    2. Avidor Y, Nadu A, Matzkin H. Clinical significance of gross hematuria and its evaluation in patients receiving anticoagulant and aspirin treatment. Urology 2000; 55: 22-24. Go to original source... Go to PubMed...
    3. Daniels PR. Therapy insight: management of urology patients taking long-term warfarin anticoagulation therapy. Nat Clin Pract Urol 2005; 2(7): 343-350. Go to original source... Go to PubMed...
    4. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S. Go to original source... Go to PubMed...
    5. Gumulec J, Penka M, Bezděk R, et al. Prevence žilní trombózy a plicní embolizace v chirurgii, v laparoskopické chirurgii, v cévní chirurgii a v urologii. Vnitř. Lék. 2006; 52(S1), 35-40. Go to original source...
    6. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188S-203S. Go to original source... Go to PubMed...
    7. Chlumský J, et al. Antikoagulační léčba. Praha: Grada Publishing 2005: 220 s.
    8. Matýšková M, Penka M. Interakce antikoagulačních léků s potravinami a potravinovými doplňky. Interní med. 2005; 5: 29-33.
    9. Meyer JP, Gillatt DA, Lush R, et al. Managing the warfarinized urological patient. BJU Int 2003; 92(4): 351-354. Go to original source... Go to PubMed...
    10. Patrono C, Coller B, Fitzgerald GA, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 234S-264S. Go to original source... Go to PubMed...
    11. Penka M, Buliková A, Gumulec J, et al. Příprava nemocných na dlouhodobé antikoagulační léčbě kumariny k invazivním zákrokům. Vnitř. Lék. 2006; 52(S1), 41-50.
    12. Rang HP, Dale MM, Ritter JM, Flower RJ. Haemostasis and thrombosis. In: Rang and Dale's Pharmacology. Churchill Livingstone Elsevier Philadelphia, 2007: 341 s. Go to original source...
    13. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-574. Go to original source... Go to PubMed...
    14. Thromboembolic Risk Factors (THRiFT II) Consensus - Second Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology 1998; 13: 87-97. Pozn.: Summary of product characteristics (SPC) jednotlivých látek a léků jsou k dispozici na stránkách Státního ústavu pro kontrolu léčiv (www.sukl.cz/modules/medication/search.php). Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.